Literature DB >> 8395303

Differential alterations in adenosine A1 and kappa 1 opioid receptors in the striatum in Alzheimer's disease.

M Ikeda1, K B Mackay, D Dewar, J McCulloch.   

Abstract

The alterations in Alzheimer's disease (AD) of two binding sites in the striatum suggested to have a presynaptic localisation have been investigated by quantitative ligand binding autoradiography. Adenosine A1 binding sites labelled with [3H]cyclohexyladenosine (CHA) and kappa 1 opioid binding sites labelled with [3H]U-69593 were studied in adjacent sections of the striatum obtained postmortem from 10 patients with AD and 9 matched controls. In AD, there was a significant reduction of [3H]CHA binding sites in the caudate nucleus (control = 88 +/- 4; AD = 56 +/- 6 pmol/g tissue; mean +/- S.E.M.) and putamen (control = 83 +/- 4; AD = 58 +/- 7 pmol/g). In control subjects, highest levels of [3H]U-69593 binding were localised to patches within the caudate nucleus (9.66 +/- 0.58 pmol/g) with lower levels in the matrix (5.54 +/- 0.48 pmol/g). There was no alteration in [3H]U-69593 binding sites in either the caudate nucleus (patches and matrix) or putamen of AD patients. The activity of choline acetyltransferase (ChAT), determined in the same tissue samples used for autoradiographic analysis, was significantly reduced in AD (control = 124 +/- 11; AD = 64 +/- 14 nmol/h/mg protein). There was a positive correlation between ChAT activity and [3H]CHA binding (r = 0.769), but not [3H]U-69593 binding (r = 0.197). The results indicate that a marked loss of adenosine A1 receptors occurs in the striatum of AD with no loss of kappa 1 opioid receptors, and that the loss of A1 receptors parallels the loss of choline acetyltransferase activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395303     DOI: 10.1016/0006-8993(93)90211-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 2.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

3.  Laminar distribution of the multiple opioid receptors in the human cerebral cortex.

Authors:  J M Hiller; L Q Fan
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

4.  The role of adenosine in Alzheimer's disease.

Authors:  Anisur Rahman
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 5.  Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness.

Authors:  Gabriel S Chiu; Gregory G Freund
Journal:  Metabolism       Date:  2014-09-26       Impact factor: 8.694

Review 6.  Adenosine receptor signalling in Alzheimer's disease.

Authors:  Phuc N H Trinh; Jo-Anne Baltos; Shane D Hellyer; Lauren T May; Karen J Gregory
Journal:  Purinergic Signal       Date:  2022-07-23       Impact factor: 3.950

7.  Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors.

Authors:  D K Von Lubitz; J Kim; M Beenhakker; M F Carter; R C Lin; Y Meshulam; J W Daly; D Shi; L M Zhou; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1995-09-05       Impact factor: 4.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.